Tuberculosis News and Research RSS Feed - Tuberculosis News and Research

Tuberculosis (TB) is a bacterial infection caused by a germ called Mycobacterium tuberculosis. The bacteria usually attack the lungs, but they can also damage other parts of the body. TB spreads through the air when a person with TB of the lungs or throat coughs, sneezes or talks. If you think you have been exposed, you should go to your doctor for tests as soon as possible. You are more likely to get TB if you have a weak immune system.
Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis. [More]
Researchers investigate impact of nutrition in resource-poor regions on infant brain development

Researchers investigate impact of nutrition in resource-poor regions on infant brain development

Brain activity of babies in developing countries could be monitored from birth to reveal the first signs of cognitive dysfunction, using a new technique piloted by a London-based university collaboration. [More]

Automated diagnostic technologies redefine infectious diseases

The diagnostics market for infectious diseases such as tuberculosis (TB), human immunodeficiency virus (HIV), hepatitis C virus and human papilloma virus is expanding, giving rise to commercial opportunities especially in the developing economies of Asia, Africa and Latin America. [More]
New device uses space-tested concept of capillary flow to diagnose infectious diseases

New device uses space-tested concept of capillary flow to diagnose infectious diseases

A new medical-testing device is being prepped to enter the battle against infectious disease. This instrument could improve diagnosis of certain diseases in remote areas, thanks in part to knowledge gained from a series of investigations aboard the International Space Station on the behavior of liquids. The device uses the space-tested concept of capillary flow to diagnose infectious diseases such as HIV/AIDS and tuberculosis. [More]
Drug used to treat TB may also act against various infections, says study

Drug used to treat TB may also act against various infections, says study

A drug under clinical trials to treat tuberculosis could be the basis for a class of broad-spectrum drugs that act against various bacteria, fungal infections and parasites, yet evade resistance, according to a study by University of Illinois chemists and collaborators. [More]
Deaths from viral Hepatitis B and C exceed deaths caused by HIV/AIDS

Deaths from viral Hepatitis B and C exceed deaths caused by HIV/AIDS

Deaths from viral Hepatitis B and C have surpassed HIV/AIDS in many countries, including Australia and in Western Europe, according to an analysis of the 2010 Global Burden of Disease study. [More]

Researchers examine effects of introducing rapid diagnostic tests for malaria in Africa

Researchers from the Cochrane Infectious Diseases Group conducted a review of the effects of introducing rapid diagnostic tests (RDTs) for diagnosing malaria in primary healthcare settings in Africa where laboratory services are unavailable. [More]
Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%. [More]

Housing projects in developing world expose low-income workers to natural disasters, disease

Satellite city projects across the developing world are putting an increasing number of poor people at risk to natural hazards and climate change, according to a new study from the University of Colorado Denver. [More]

Rare case of tuberculous otitis media described

South Korean researchers have reported a rare case of tuberculous otitis media and say that ear tuberculosis should be considered in patients presenting with otitis media complicated by facial paralysis. [More]
Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Otsuka inks agreement with Eisai to acquire rights to hematological cancer treatment Dacogen

Otsuka Pharmaceutical Co., Ltd. has announced an agreement with Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment Dacogen and to an enzyme inhibitor, E7727. [More]

Anacor Pharmaceuticals enrolls first patient in AN2728 Phase 3 trial for treatment of atopic dermatitis

Anacor Pharmaceuticals announced today that the first patient has been enrolled in the Phase 3 trial of AN2728, a novel boron-based phosphodiesterase-4 (PDE-4) inhibitor, for the topical treatment of mild-to-moderate atopic dermatitis. Atopic dermatitis is a chronic rash characterized by inflammation and itch and affects approximately 10% - 20% of infants and young children. [More]

New policy report on multi-drug resistant tuberculosis

Leading politicians, officials, researchers and civil society organisations convened in Brussels at the launch of European Voice’s multi-drug resistant (MDR-TB) policy report in the lead up to World TB day, to discuss the rising incidence of MDR-TB, the need for more effective treatments, new vaccines and better diagnostics and what needs to done at a European level to tackle this preventable disease. [More]
Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

Insmed Incorporated today reported results from the Company's phase 2 clinical trial of ARIKAYCETM, or liposomal amikacin for inhalation, for the treatment of patients with treatment resistant nontuberculous mycobacterial (NTM) lung infections. [More]

Viewpoints: Be careful what you pray for; health law 'freakouts;' concerns about imported drugs

On Tuesday, the Supreme Court will consider a proposition that will strike many Americans as bizarre: that large, for-profit businesses can refuse on religious grounds to comply with a federal mandate that they include contraception in their employee health plans (3/25). [More]
ASU scientist selected as 2014 recipient of Lifetime Achievement Award

ASU scientist selected as 2014 recipient of Lifetime Achievement Award

Roy Curtiss III, a scientist at the Biodesign Institute at Arizona State University, has been selected as the 2014 recipient of the Lifetime Achievement Award from the American Society for Microbiology. [More]

IDRI awarded grant extension of $3.4M for identifying new leads and drug targets for tuberculosis

IDRI's​ drug discovery efforts continue to grow with a recently awarded grant extension of $3.4 million from the Bill & Melinda Gates Foundation. The additional funding was awarded to Tanya Parish, Ph.D., IDRI's Vice President of Drug Discovery, and supplements an earlier grant awarded in 2010, for a total of $7.8 million. [More]
Tobacco smoking increases risk of recurrent TB, shows study

Tobacco smoking increases risk of recurrent TB, shows study

Research published today provides critical new insight on the harmful links between smoking tobacco and developing tuberculosis (TB). [More]

Tuberculosis control needs a complete and patient-centric solution

Whether it is mobile phone service or vacation travel, good businesses know that success depends on providing a complete and customer-centric solution. Should patients with tuberculosis not be offered a complete solution that is patient-centered? After all, millions are affected and a large market at the base-of-the-pyramid (BoP) remains unserved. [More]
Climate change could increase death rates in London and southeast England, scientists predict

Climate change could increase death rates in London and southeast England, scientists predict

Warmer summers brought on by climate change will cause more deaths in London and southeast England than the rest of the country, scientists predict. [More]